Teriparatide (recombinant human parathyroid hormone 1-34) for the treatment of osteoporosis: a review

VernacularTitle:特立帕肽(重组人甲状旁腺素1-34)在骨质疏松治疗中的应用
Publication Type:Journal Article
Keywords: Bone markers; Bone mineral density; Bone quality; Fracture; Osteoporosis; Teriparatide
From: Chinese Journal of Endocrinology and Metabolism 2013;29(12):后插3-后插9
CountryChina
Language:Chinese
Abstract: Teriparatide is an injectable recombinant human parathyroid hormone (1-34) [rhPTH(1-34)],which has been approved for the treatment of osteoporosis worldwide,including China since 2011.In pre-clinical studies,teriparatide was shown to exhibit anabolic effects on bone with a unique mechanism of action that is distinct from that of antiresorptive agents,including bisphosphonates,selective estrogen receptor modulators (SERMs),calcitonin,and estrogen.This bone-building effect has been supported by clinical trials in men and postmenopausal women,with reductions in fracture risk,and increases in bone turnover markers,including serum osteocalcin and procollagen type Ⅰ N-terminal propeptide (PINP),and bone mineral density (BMD),and improvements in bone quality.Recent studies in Asian patient populations show similar results and support the findings for bone markers and BMD when compared with current antiresorptive medications.